[Management of high blood pressure and cardiac insufficiency. New drugs and therapeutic concepts].
Schäfer
Stefan
S
Aventis Pharma Deutschland GmbH Gebäude G 879 65926 Frankfurt am Main. Andreas.Busch@aventis.com
Busch
Andreas E
AE
D000595:Amino Acid Sequence; D000818:Animals; D020013:Calcium Signaling / Q000187:drug effects; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000503:physiopathology; D016207:Cytokines / Q000037:antagonists & inhibitors; D016232:Endothelins / Q000037:antagonists & inhibitors; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D008969:Molecular Sequence Data; D020097:Natriuretic Peptide, Brain / Q000502:physiology; D010447:Peptide Hydrolases / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D014667:Vasopressins / Q000037:antagonists & inhibitors
D016207:Cytokines; D016232:Endothelins; D000451:Mineralocorticoid Receptor Antagonists; D017923:Sodium-Hydrogen Exchangers; D014667:Vasopressins; D020097:Natriuretic Peptide, Brain; D010447:Peptide Hydrolases